The authors and publisher would like to make the following corrections to this article:
Demonstration of Clinical Comparability of the Biosimilar Filgrastim to
The authors and publisher would like to make the following corrections to this article:
In the sub-section Phase III, KWI-300-104 on page 113, the percentage of adverse events described as severe should read 8.14 %.
The corrected statement reads:
Most AEs were described as mild in severity (748 events, 61.51 %). AEs were described as moderate in 368 (30.26 %), severe in 99 (8.14 %) and life threatening in one (0.08 %) case.
In Figure 4 the vertical axis should read "ANC (G/l)" instead of "ANC (mg/l)".
